Here is an example of what happens when a company
Post# of 72447
(Total Views: 227)
Posted On: 09/12/2017 6:59:08 PM
Here is an example of what happens when a company takes on toxic financing and then gets attacked by Mako:
OCAT.
OCAT had very promising clinical trial results -- the last batch of which were released less than a week after the last attack of several nasty attacks by Mako, published on Seeking Alpha.
OCAT (which "coincidentally" was a Boston biotech, hmmm) was forced to accept a horrible buyout deal, because they had taken on toxic financing. Most shareholders lost money, except for those who bought low after the Mako attack. Long-term shareholders lost money, bigtime. I know because I was one of those.
Does anyone see a pattern here? Company attacked by Mako repeatedly, with lots of lies involved (OCAT also had that "empty office, it's a scam" business thrown at it) -- and then when the technology turns out to work, a big pharma swoops in to buy its assets. Cause and effect? We are aware that at least one and probably two Swiss biotechs have been known to be involved in these kinds of activities in the past.
This is why people should be grateful to Leo Ehrlich, instead of listening to those bashers who attack him. He's kept IPIX from taking on the kinds of problematic financing that OCAT, AMBS, well, just name 'em -- so many small biotechs have gotten killed by doing. Leo Ehrlich knows better than to do that.
And that is why there must be a certain amount of consternation among the bashers and perhaps some pharmaceutical executives. They're not going to be able to do this to IPIX.
OCAT.
OCAT had very promising clinical trial results -- the last batch of which were released less than a week after the last attack of several nasty attacks by Mako, published on Seeking Alpha.
OCAT (which "coincidentally" was a Boston biotech, hmmm) was forced to accept a horrible buyout deal, because they had taken on toxic financing. Most shareholders lost money, except for those who bought low after the Mako attack. Long-term shareholders lost money, bigtime. I know because I was one of those.
Does anyone see a pattern here? Company attacked by Mako repeatedly, with lots of lies involved (OCAT also had that "empty office, it's a scam" business thrown at it) -- and then when the technology turns out to work, a big pharma swoops in to buy its assets. Cause and effect? We are aware that at least one and probably two Swiss biotechs have been known to be involved in these kinds of activities in the past.
This is why people should be grateful to Leo Ehrlich, instead of listening to those bashers who attack him. He's kept IPIX from taking on the kinds of problematic financing that OCAT, AMBS, well, just name 'em -- so many small biotechs have gotten killed by doing. Leo Ehrlich knows better than to do that.
And that is why there must be a certain amount of consternation among the bashers and perhaps some pharmaceutical executives. They're not going to be able to do this to IPIX.
(5)
(0)